A population based case-control study of oral moroxydine, an antiviral agent treatment during pregnancy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated. The objective of the study was to check the effect of oral moroxydine, a biguanide antiviral drug during pregnancy for birth outcomes. First, the prevalence of moroxydine use in the mothers of cases with and controls without congenital abnormalities was compared. Of 38,151 pregnant women who delivered newborn infants without any defects (control group), 14 (0.04%), while of 22,843 pregnant women who had fetuses or newborns with congenital abnormalities, 13 (0.06%) were treated with the oral tablet of moroxydine (POR with 95% CI: 1.6, 0.7-3.3). The teratogenic potential of oral moroxydine treatment cannot be excluded because a higher use of moroxydine during the second-third month of pregnancy was found in the mothers of multi malformed cases and of anencephalic fetuses, though these possible associations were based only on two-two cases. Second, control newborn infants without any defect born to mothers with or without moroxydine treatment were compared. A somewhat larger mean birth weight (3.532±426 vs. 3.276±511, adjusted t = 1.8; p = 0.07) and a reduction of low birth weight (0 vs. 9.2%) was found in control newborn infants of the mothers with moroxydine treatment. The weak teratogenic potential and some birth weight promotion effect of moroxydine treatment during pregnancy may deserve some attention.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
JournalInternational Journal of Pharmacology
Volume2
Issue number2
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Antiviral Agents
Case-Control Studies
Pregnancy
Population
Mothers
Newborn Infant
Therapeutics
Birth Weight
Pregnant Women
Fetus
Biguanides
moroxydine
Low Birth Weight Infant
Pregnancy Outcome
Tablets
Parturition
Control Groups

Keywords

  • Birth weight
  • Case-control study
  • Congenital abnormalities
  • Low birth weight
  • Moroxydine

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{91a6bf618c8e4cdf8a5d8244fc446619,
title = "A population based case-control study of oral moroxydine, an antiviral agent treatment during pregnancy",
abstract = "The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated. The objective of the study was to check the effect of oral moroxydine, a biguanide antiviral drug during pregnancy for birth outcomes. First, the prevalence of moroxydine use in the mothers of cases with and controls without congenital abnormalities was compared. Of 38,151 pregnant women who delivered newborn infants without any defects (control group), 14 (0.04{\%}), while of 22,843 pregnant women who had fetuses or newborns with congenital abnormalities, 13 (0.06{\%}) were treated with the oral tablet of moroxydine (POR with 95{\%} CI: 1.6, 0.7-3.3). The teratogenic potential of oral moroxydine treatment cannot be excluded because a higher use of moroxydine during the second-third month of pregnancy was found in the mothers of multi malformed cases and of anencephalic fetuses, though these possible associations were based only on two-two cases. Second, control newborn infants without any defect born to mothers with or without moroxydine treatment were compared. A somewhat larger mean birth weight (3.532±426 vs. 3.276±511, adjusted t = 1.8; p = 0.07) and a reduction of low birth weight (0 vs. 9.2{\%}) was found in control newborn infants of the mothers with moroxydine treatment. The weak teratogenic potential and some birth weight promotion effect of moroxydine treatment during pregnancy may deserve some attention.",
keywords = "Birth weight, Case-control study, Congenital abnormalities, Low birth weight, Moroxydine",
author = "E. Czeizel and E. Puh{\'o} and N. {\'A}cs and F. B{\'a}nhidy",
year = "2006",
month = "3",
doi = "10.3923/ijp.2006.188.192",
language = "English",
volume = "2",
pages = "188--192",
journal = "International Journal of Pharmacology",
issn = "1811-7775",
publisher = "Asian Network for Scientific Information",
number = "2",

}

TY - JOUR

T1 - A population based case-control study of oral moroxydine, an antiviral agent treatment during pregnancy

AU - Czeizel, E.

AU - Puhó, E.

AU - Ács, N.

AU - Bánhidy, F.

PY - 2006/3

Y1 - 2006/3

N2 - The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated. The objective of the study was to check the effect of oral moroxydine, a biguanide antiviral drug during pregnancy for birth outcomes. First, the prevalence of moroxydine use in the mothers of cases with and controls without congenital abnormalities was compared. Of 38,151 pregnant women who delivered newborn infants without any defects (control group), 14 (0.04%), while of 22,843 pregnant women who had fetuses or newborns with congenital abnormalities, 13 (0.06%) were treated with the oral tablet of moroxydine (POR with 95% CI: 1.6, 0.7-3.3). The teratogenic potential of oral moroxydine treatment cannot be excluded because a higher use of moroxydine during the second-third month of pregnancy was found in the mothers of multi malformed cases and of anencephalic fetuses, though these possible associations were based only on two-two cases. Second, control newborn infants without any defect born to mothers with or without moroxydine treatment were compared. A somewhat larger mean birth weight (3.532±426 vs. 3.276±511, adjusted t = 1.8; p = 0.07) and a reduction of low birth weight (0 vs. 9.2%) was found in control newborn infants of the mothers with moroxydine treatment. The weak teratogenic potential and some birth weight promotion effect of moroxydine treatment during pregnancy may deserve some attention.

AB - The data of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated. The objective of the study was to check the effect of oral moroxydine, a biguanide antiviral drug during pregnancy for birth outcomes. First, the prevalence of moroxydine use in the mothers of cases with and controls without congenital abnormalities was compared. Of 38,151 pregnant women who delivered newborn infants without any defects (control group), 14 (0.04%), while of 22,843 pregnant women who had fetuses or newborns with congenital abnormalities, 13 (0.06%) were treated with the oral tablet of moroxydine (POR with 95% CI: 1.6, 0.7-3.3). The teratogenic potential of oral moroxydine treatment cannot be excluded because a higher use of moroxydine during the second-third month of pregnancy was found in the mothers of multi malformed cases and of anencephalic fetuses, though these possible associations were based only on two-two cases. Second, control newborn infants without any defect born to mothers with or without moroxydine treatment were compared. A somewhat larger mean birth weight (3.532±426 vs. 3.276±511, adjusted t = 1.8; p = 0.07) and a reduction of low birth weight (0 vs. 9.2%) was found in control newborn infants of the mothers with moroxydine treatment. The weak teratogenic potential and some birth weight promotion effect of moroxydine treatment during pregnancy may deserve some attention.

KW - Birth weight

KW - Case-control study

KW - Congenital abnormalities

KW - Low birth weight

KW - Moroxydine

UR - http://www.scopus.com/inward/record.url?scp=33646174037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646174037&partnerID=8YFLogxK

U2 - 10.3923/ijp.2006.188.192

DO - 10.3923/ijp.2006.188.192

M3 - Article

AN - SCOPUS:33646174037

VL - 2

SP - 188

EP - 192

JO - International Journal of Pharmacology

JF - International Journal of Pharmacology

SN - 1811-7775

IS - 2

ER -